33 results on '"*ANAPLASTIC lymphoma kinase"'
Search Results
2. ハイガン ヤクブツ リョウホウ ノ レキシ ト ガン メンエキ リョウホウ ノ ハッテン
- Subjects
clinical trials ,Anaplastic lymphoma kinase ,ALK ,EGFR ,免疫療法 ,免疫関連有害事象 ,immunotherapy ,臨床試験 ,epidermal growth factor receptor - Abstract
先人の英知と努力による多くの臨床比較試験により, 肺がんに対する治療戦略は構築されてきた, 薬物療法の歴史は, まさに臨床試験の歴史そのものである.肺がんの薬物療法は殺細胞性抗がん剤, 血管新生阻害剤, 分子標的療法, 免疫療法に分類される.分子標的療法は, 遺伝子変異をターゲットとした治療である.現在までにepidermal growth factor receptor(EGFR)遺伝子変異を有する非小細胞肺がんを対象にEGFR阻害剤と殺細胞性抗がん剤を比較した第III相試験が複数報告されており, EGFR阻害剤群が無増悪生存期間で有意に良好な結果を示している. ……, Treatment strategies for lung cancer have been developed based on many clinical trials by the wisdom and efforts of the predecessor. The history of anticancer drugs is exactly the history of clinical trials. Drug therapy for lung cancer is classified as a cytotoxic drug, angiogenesis inhibitor, molecular targeted therapy, immunotherapy. Molecular targeted therapy is a treatment for targeting gene mutations. Several Phase III trials comparing epidermal growth factor receptor (EGFR) inhibitors with cytotoxic agents have been reported in lung cancer patients with EGFR mutation, which showed that EGFR inhibitor is significantly better in progression-free survival....
- Published
- 2018
3. [Successful alectinib monotherapy for residual disease after brentuximab vedotin combined chemotherapy in ALK-positive anaplastic large cell lymphoma].
- Author
-
Sakata M, Saburi M, Kawano K, Takata H, Miyazaki Y, Nagamatsu K, Gamachi A, and Ohtsuka E
- Subjects
- Adult, Anaplastic Lymphoma Kinase, Brentuximab Vedotin therapeutic use, Carbazoles therapeutic use, Humans, Male, Neoplasm, Residual, Piperidines, Lymphoma, Large-Cell, Anaplastic drug therapy
- Abstract
A 28-year-old male patient presented with multiple lymphadenopathies and extranodal masses. He was diagnosed with stage IVB ALK-positive anaplastic large cell lymphoma after the right axillary lymph node biopsy. A partial metabolic response with fluorodeoxyglucose accumulation was observed in the residual disease of the upper left hilar lymph node after eight courses of brentuximab vedotin, cyclophosphamide, adriamycin, and prednisolone. We started alectinib at 600 mg daily, which achieved a complete metabolic response (CMR) after three months. The CMR was maintained and alectinib was continuously administered without adverse events at the last follow up. Alectinib showed high efficacy and tolerability, though the optimal period and long-term adverse effects of administration remain unclear. Therefore, further studies are necessary.
- Published
- 2022
- Full Text
- View/download PDF
4. A case of anaplastic lymphoma kinase-positive non-small cell lung cancer with a poor performance status successfully treated with crizotinib
- Subjects
crizotinib ,performance status ,anaplastic lymphoma kinase ,non-small cell lung cancer - Abstract
A 27-year-old female was referred to our hospital for further examination of hoarseness, cough, and hemoptysis. Positron emission tomography-computed tomography revealed FDG accumulation in a huge mass in the left lower lobe, lymph nodes in the hilum, mediastinum and right cervical lesion left scapula and vertebral body. Further examination yielded the diagnosis of primary lung adenocarcinoma (cT2aN3M1b : Stage IV) harboring the anaplastic lymphoma kinase (ALK) fusion oncogene. Although her general condition was getting worse due to rapid increase of the pleural effusion, crizotinib promptly diminish the pleural effusion and ameliorated the patient’s condition. The adverse events of crizotinib, such as nausea, vomiting and visual disturbance, were generally mild and well tolerable during treatment. These findings suggest that crizotinib is a promising candidate for ALK-positive non-small cell lung cancer patients even with poor performances.
- Published
- 2015
5. 転座型腎細胞癌up-to-date
- Subjects
転座 ,免疫組織化学 ,ヒト第11染色体 ,ヒト ,Fluorescence in Situ Hybridization ,Receptor Protein-Tyrosine Kinases ,Anaplastic Lymphoma Kinase ,ヒト第6染色体 ,腎細胞癌(遺伝学,病理学) - Published
- 2015
6. [Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation].
- Author
-
Yamazaki R, Koda Y, Abe R, Sakurai M, Kikuchi T, Kato J, Ouchi T, Mikami S, and Mori T
- Subjects
- Adult, Anaplastic Lymphoma Kinase, Female, Humans, Neoplasm Recurrence, Local, Receptor Protein-Tyrosine Kinases, Remission, Spontaneous, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, Lymphoma, Large-Cell, Anaplastic therapy
- Abstract
A 44-year-old woman was diagnosed with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) with clinical stage IVA (nodal and bladder involvement). Complete response (CR) was achieved after the CHOP chemotherapy; however, 12 months after the last course of chemotherapy, ALCL relapsed in the form of skin lesions without nodal involvement. After achieving a second CR with chemotherapy, autologous stem cell transplantation was performed. Two months after transplantation, the disease again relapsed as multiple skin lesions. Electron beam irradiation was performed; however, other skin lesions appeared thereafter and spontaneously disappeared. At present, 3.4 years after the transplantation, the patient is free from disease. ALK-positive ALCL relapsing as skin lesions may behave differently from the nodal relapse. An accumulation of cases is required to elucidate ALCL characteristics relapsing as skin lesions.
- Published
- 2021
- Full Text
- View/download PDF
7. A case of inflammatory myofibroblastic tumor of the urinary bladder finally diagnosed by anaplastic lymphoma kinase (ALK) immunostaining
- Author
-
Takeshita, Hideki, Kawakami, Satoru, Okubo, Yuhei, Yamamoto, Shinya, Yonese, Junji, Fukui, Iwao, Kono, Atsushi, Kurata, Morito, Inoshita, Naoko, and Ishikawa, Yuichi
- Subjects
Inflammatory pseudotumor ,Inflammatory myofibroblastic tumor ,Anaplastic lymphoma kinase ,494.9 ,Urinary bladder - Abstract
52歳女.患者は排尿時痛を主訴とした.腫瘍マーカーは正常範囲内であったが, 膀胱鏡所見では左後三角部に径3cm, 周囲に浮腫を伴う充実性非乳頭状腫瘍が認められた.更にMRIでは腫瘍はT1, T2強調画像ともに低信号で描出され, 造影効果が強く, 膀胱筋層への浸潤が認められた.病理組織学的所見では一部に上皮成分を混じえた大型の異型紡錘形細胞の浸潤性増生を認め, 膀胱肉腫様癌(cT2bN0m0)と診断された.前方骨盤内臓全摘・導尿型新膀胱造設術を施行したところ, 全摘標本の病理組織学的所見は紡錘形細胞の増生を認めたが, 上皮細胞の増殖は認めなかった.紡錘形細胞はcytokeratin, vimentin, smooth muscle actinに加え, anaplastic lymphoma kinase(ALK)も陽性で, 膀胱の炎症性筋線維芽細胞性腫瘍と確診された.術後1年経過現在, 再発は認められていない, A 52-year-old house wife presented with pain on urination. Cystoscopy and magnetic resonance imaging revealed solid and sessile tumor of 3 cm in diameter invading the bladder wall. Pathological examination of the transurethral resection specimen showed proliferation of spindle cells and epithelial cells. Since both types of cells were positive for cytokeratin immunostaining, sarcomatoid carcinoma was highly suspected. She underwent anterior pelvic exenteration and construction of continent reservoir (Penn Pouch). Since the tumor cells showed spindle cell proliferation alone without epithelial growth and positive staining for anaplastic lymphoma kinase, we corrected the final diagnosis as an inflammatory myofibroblastic tumor of the urinary bladder. She has been doing well without recurrence for 1 year.
- Published
- 2006
8. [A Pulmonary Mucoepidermoid Carcinoma with Anaplastic Lymphoma Kinase Fusion Responding to Alectinib Hydrochloride].
- Author
-
Onodera K, Sato N, Kobayashi K, and Kurotaki H
- Subjects
- Adult, Anaplastic Lymphoma Kinase, Carbazoles, Female, Humans, Lymph Node Excision, Piperidines, Carcinoma, Mucoepidermoid, Lung Neoplasms
- Abstract
Few cases of lung mucoepidermoid carcinomas with anaplastic lymphoma kinase (ALK) fusion have been reported. A 35-year-old woman was found to have an abnormal chest X-ray. A tumor and obstructive pneumonitis in her left upper lobe was detected using computed tomography (CT). She was admitted to our hospital, and was diagnosed with mucoepidermoid carcinoma by transbronchial biopsy. Left pneumonectomy and lymphadenectomy were performed for lung mucoepidermoid carcinoma and a mediastinal lymph node metastasis (pT2aN2M0, stage ⅢA). Postoperative radiotherapy (50 Gy) to the mediastinum and chemotherapy were performed followed by several radiotherapies for cervical and mediastinal lymph node and right ischium metastases. Since then, further radiotherapy was impossible. However, we detected ALK fusion in the resected specimen and the cancer responded to alectinib hydrochloride.
- Published
- 2019
9. [Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events].
- Author
-
Satouchi M, Nishio M, Hida T, and Nakagawa K
- Subjects
- Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents adverse effects, Clinical Trials as Topic, Humans, Lung Neoplasms pathology, Protein Kinase Inhibitors adverse effects, Pyrimidines adverse effects, Sulfones adverse effects, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Sulfones therapeutic use
- Abstract
The advent of anaplastic lymphoma kinase(ALK)inhibitors has revolutionized treatment of ALK fusion gene-positive nonsmall cell lung cancer(NSCLC). Nevertheless, it has become clear that cases refractory and resistant to ALK inhibitors occur at a certain incidence, and how to treat such cases is a current issue. Following crizotinib and alectinib, ceritinib(Zykadia® capsules)is the third ALK inhibitor approved in Japan, and it is expected to be useful for patients who have developed crizotinib resistance. However, ceritinib has been pointed out to have a high incidence of gastrointestinal adverse events that impact patients' quality of life. Accordingly, in this paper, we report the clinical results and incidence of gastrointestinal adverse reactions with ceritinib in treatment of ALK-positive NSCLC patients. We also present management methods of the adverse events.
- Published
- 2018
10. [A case of primary central nervous system anaplastic lymphoma kinase positive anaplastic large cell lymphoma manifested as a unilateral pachymeningits].
- Author
-
Fujisawa E, Shibayama H, Mitobe F, Katada F, Sato S, and Fukutake T
- Subjects
- Adult, Anaplastic Lymphoma Kinase, Central Nervous System Neoplasms diagnosis, Central Nervous System Neoplasms pathology, Dura Mater pathology, Epilepsy, Generalized etiology, Humans, Lymphoma, Large-Cell, Anaplastic diagnosis, Lymphoma, Large-Cell, Anaplastic pathology, Magnetic Resonance Imaging, Male, Meningitis diagnostic imaging, Neoplasm Invasiveness, Central Nervous System Neoplasms complications, Central Nervous System Neoplasms enzymology, Lymphoma, Large-Cell, Anaplastic complications, Lymphoma, Large-Cell, Anaplastic enzymology, Meningitis etiology, Receptor Protein-Tyrosine Kinases metabolism
- Abstract
There have been 23 reports of primary central nervous system anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma in the literature. Here we report the 24th case of a 40-year-old man who presented with occipital headache for one month. His contrast-enhanced brain MRI showed enhancement around the right temporal lobe, which suggested a diagnosis of hypertrophic pachymeningitis. He improved with steroid therapy. After discharge, however, he was readmitted with generalized convulsive seizures. Finally, he was diagnosed as primary central nervous system ALK-positive anaplastic large cell lymphoma by brain biopsy. Primary central nervous system lymphoma invading dura matter can rarely manifests as a unilateral pachymeningitis. Therefore, in case of pachymeningitis, we should pay attention to the possibility of infiltration of lymophoma with meticulous clinical follow-up.
- Published
- 2017
- Full Text
- View/download PDF
11. [Subtotal Esophagectomy for Mediastinal Lymph Node Oligo-Recurrence of ALK-Positive Lung Adenocarcinoma - A Case Report].
- Author
-
Tetsumoto S, Okada K, Nagata H, Toyota S, Tanaka S, Niki T, Tsuruta N, Higaki N, Niju T, Oka Y, Nezu R, and Ikeda T
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma metabolism, Adenocarcinoma of Lung, Anaplastic Lymphoma Kinase, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Lymphatic Metastasis, Mediastinum pathology, Middle Aged, Quality of Life, Receptor Protein-Tyrosine Kinases metabolism, Recurrence, Treatment Outcome, Adenocarcinoma surgery, Esophagectomy, Lung Neoplasms surgery, Mediastinum surgery
- Abstract
The patient was a 54-year-old woman with anaplastic lymphoma kinase-positive stage III B lung cancer. She received 4 courses of carboplatin(CBDCA)plus paclitaxel(PTX)plus bevacizumab(Bev)chemotherapy and crizotinib. Chemotherapy reduced the size of the primary site and mediastinal lymphadenopathy; however, the right supraclavicular and subcarinal lymph nodes were enlarged again during crizotinib treatment. Because it was an oligo-recurrence, we performed radiotherapy for these lymph nodes and changed systemic chemotherapy to alectinib. After 16 months, the patient exhibited esophageal stenosis due to subcarinal lymphadenopathy. We performed a subtotal esophagectomy, which improved the quality of life, and she was continued on an oral treatment of alectinib. Therefore, we suggest that an invasive surgical treatment is useful for oligo-recurrence cases.
- Published
- 2017
12. ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin.
- Author
-
Arai H, Furuichi S, Nakamura Y, Nakamura Y, Ichikawa M, and Mitani K
- Subjects
- Anaplastic Lymphoma Kinase, Brentuximab Vedotin, Female, Humans, Ki-1 Antigen analysis, Lymphoma, Large-Cell, Anaplastic chemistry, Lymphoma, Large-Cell, Anaplastic metabolism, Middle Aged, Receptor Protein-Tyrosine Kinases analysis, Treatment Outcome, Immunoconjugates therapeutic use, Ki-1 Antigen immunology, Lymphoma, Large-Cell, Anaplastic drug therapy
- Abstract
A 59-year-old woman with anaplastic large cell lymphoma (ALCL), ALK-negative, was treated with brentuximab vedotin (BV) against relapse after 6 regimens of systemic chemotherapy and radiation. Despite achieving an initial response, skin lesions worsened after 11 courses. A skin biopsy after the development of resistance to BV confirmed loss of CD30 expression by the tumor cells, suggesting a possible cause of resistance. This case shows that down-regulation of CD30 does occur during BV treatment, resulting in resistance to this drug. Because of this possibility, in the future, expression of CD30 should be carefully monitored with extended use of BV against ALCL.
- Published
- 2016
- Full Text
- View/download PDF
13. [Companion Diagnostics for Solid Tumors].
- Author
-
Watanabe A
- Subjects
- Anaplastic Lymphoma Kinase, Biomarkers, Tumor, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Cetuximab therapeutic use, Colonic Neoplasms drug therapy, Colonic Neoplasms genetics, Crizotinib, Drug Discovery, ErbB Receptors, Gefitinib, Gene Fusion genetics, Guidelines as Topic, Humans, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Molecular Targeted Therapy, Pharmacogenetics, Precision Medicine, Proto-Oncogene Proteins p21(ras) genetics, Pyrazoles therapeutic use, Pyridines therapeutic use, Quinazolines therapeutic use, Receptor Protein-Tyrosine Kinases genetics, Receptor, ErbB-2 genetics, Trastuzumab therapeutic use, Breast Neoplasms diagnosis, Colonic Neoplasms diagnosis, Diagnostic Uses of Chemicals, Lung Neoplasms diagnosis, Molecular Diagnostic Techniques
- Abstract
Companion diagnostics (CoDx) will likely continue to rapidly increase in number and application to disease areas including solid tumors, for example EGFR for gefitinib and ALK fusion gene for crizotinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; HER2 for trastuzumab in breast cancer. CoDx are an indispensable part of personalized medicine and pharmacogenomics. In CoDx development, there are still many challenges, such as the business model promoting cooperation between diagnostics and pharmaceutical companies, and also the regulations related to CoDx. The FDA notice on the development of CoDx in 2011 recommended the co-development of a new drug and CoDx as the best practice, and the Ministry of Health, Labour and Welfare in Japan also issued a statement in 2013. In addition, the recent discovery of many novel variants in the DNA sequence, advances in sequencing and genomic technology, and improved analytic methods have enabled the impact of germline and somatic mutations to be determined using multiplex diagnosis. The complex challenges to develop CoDx necessitate a close collaboration among academic institutions, regulatory authorities, and pharmaceutical companies. [Review].
- Published
- 2015
14. [Recurrence of Anaplastic Lymphoma Kinase Positive Lung Cancer Nineteen-year after the Primary Surgery].
- Author
-
Ishida J, Suzuki H, Kitamura Y, and Uchida T
- Subjects
- Adenocarcinoma enzymology, Adenocarcinoma surgery, Aged, Anaplastic Lymphoma Kinase, Humans, Lung Neoplasms enzymology, Lung Neoplasms surgery, Male, Neoplasm Recurrence, Local, Pneumonectomy, Time Factors, Adenocarcinoma pathology, Lung Neoplasms pathology, Receptor Protein-Tyrosine Kinases analysis
- Abstract
A 77-years-old man who underwent middle lobectomy for lung adenocarcinoma in our hospital 19 years ago. p-Stage IA was pointed out multiple nodules in bilateral lung fields on a medical examination. Computed tomography scan revealed a tumor measuring 34×34 mm in size in the right lower lung and other 40 small pulmonary nodules. Characteristic pattern of metastatic adenocarcinoma from the previous lung cancer was pathologically demonstrated. Immunostaining revealed anaplastic lymphoma kinase (ALK) positivity of the both specimens, which determined the diagnosis of recurrence. Long-team postoperative follow-up for ALK positive lung cancer patients is considered to be necessary especially for younger patients.
- Published
- 2015
15. [Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].
- Author
-
Yano S
- Subjects
- Anaplastic Lymphoma Kinase, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, Gene Rearrangement, Humans, Mutation, Protein Kinase Inhibitors therapeutic use, Receptor Protein-Tyrosine Kinases genetics, Drug Resistance, Neoplasm genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Molecular Targeted Therapy, Protein Kinase Inhibitors pharmacology
- Abstract
Several driver oncogenes, including EGFR mutations and ALK rearrangement, have been identified in lung cancer. The EGFR tyrosine kinase inhibitors (TKIs) and ALK-TKIs show dramatic effects against lung cancer with EGFR activating mutations and ALK rearrangements, respectively. However, 20% of EGFR mutant lung cancer patients show intrinsic resistance, and the responders almost invariably acquire resistance to EGFR-TKIs within several years. Several mechanisms, including secondary mutations in EGFR or ALK, activation of alternative pathway, have been reported to contribute to resistance to EGFR-TKIs and ALK-TKIs. New generation TKIs for overcoming resistance to EGFR-TKI or ALK-TKI are being evaluated in clinical trials. Further investigations to develop optimal therapy based on accurate diagnosis of resistant mechanism are warranted to improve the success of treatment with targeted drugs in lung cancer.
- Published
- 2015
16. [Issues of Personalized Medicine from the Viewpoint of Laboratory Medicine].
- Author
-
Nobori T
- Subjects
- Anaplastic Lymphoma Kinase, Genetic Testing, Humans, Insurance, Health, Receptor Protein-Tyrosine Kinases analysis, Precision Medicine
- Abstract
Personalized medicine is expected to provide patients with safe and effective treatment compared to conventional medical care in which patients are treated based on the diagnosis and/or histology. In personalized medicine, patients are treated based on their genetic makeup and genetic characteristics of tumor tissues in the case of cancer chemotherapy. Genomic biomarker tests are used to molecularly characterize host and tumor tissues and stratify patients for the appropriate drugs. Drugs targeting the causative genetic changes have been developed along with companion diagnostics to test such genetic changes. In this paper, I introduce the technical guidance for companion diagnostics and related drugs issued by the Pharmaceutical and Medical Devices Agency of Japan, and discuss how to carry out a concordance study of diagnostic tests for the ALK fusion gene when new ALK inhibitors are approved. The regulations for companion diagnostics should be revised frequently to keep up with advances in this area.
- Published
- 2015
17. [Notable adverse events of ALK inhibitors in patients with ALK rearranged non-small-cell lung cancer].
- Author
-
Tanimoto A and Yano S
- Subjects
- Anaplastic Lymphoma Kinase, Drug Design, Humans, Molecular Targeted Therapy, Protein Kinase Inhibitors therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Protein Kinase Inhibitors adverse effects, Receptor Protein-Tyrosine Kinases antagonists & inhibitors
- Published
- 2015
18. [Companion diagnostics with FISH assay (HER2, ALK)].
- Author
-
Hiraoka M
- Subjects
- Anaplastic Lymphoma Kinase, Breast Neoplasms diagnosis, Carcinoma, Non-Small-Cell Lung diagnosis, Gene Amplification, Humans, In Situ Hybridization, Fluorescence methods, Precision Medicine, Receptor Protein-Tyrosine Kinases metabolism, Receptor, ErbB-2 metabolism
- Abstract
In recent anti-cancer drug treatment, personalized medicine has become popular with the development of many molecularly-targeted drugs. Companion Diagnostics (CDx) identify and detect biomarkers to predict whether a drug will work or have adverse effects on patients. We developed two CDx with FISH assays, the PathVysion HER-2 DNA Probe Kit and Vysis ALK Break Apart FISH Probe Kit. The PathVysion HER-2 DNA Probe Kit is a test to detect amplification of the HER2 gene in tissue samples from breast cancer patients to aid in determining and identifying patients eligible for treatment with Trastuzumab. The Vysis ALK Break Apart FISH Probe Kit is a test to detect rearrangements involving the ALK gene in tissue samples from non-small cell lung cancer (NSCLC) patients to aid in identifying patients eligible for treatment with Crizotinib. In this article, we review the CDx, focusing on HER2 gene and ALK fusion testing.
- Published
- 2014
19. [Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
- Author
-
Yano S
- Subjects
- Anaplastic Lymphoma Kinase, Antibodies, Monoclonal, Humanized administration & dosage, Bevacizumab, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cisplatin administration & dosage, Crizotinib, Drug Discovery, Erlotinib Hydrochloride, Etoposide administration & dosage, Gefitinib, Glutamates administration & dosage, Guanine administration & dosage, Guanine analogs & derivatives, Humans, Irinotecan, Pemetrexed, Protein Kinase Inhibitors administration & dosage, Pyrazoles administration & dosage, Pyridines administration & dosage, Quinazolines administration & dosage, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Education, Medical, Continuing, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Molecular Targeted Therapy, Small Cell Lung Carcinoma drug therapy
- Published
- 2014
- Full Text
- View/download PDF
20. [Personalized medicine in non-small-cell carcinoma].
- Author
-
Iwama E, Takayama K, Baba E, and Nakanishi Y
- Subjects
- Anaplastic Lymphoma Kinase, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin administration & dosage, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell genetics, Cisplatin administration & dosage, Humans, Mutation, Protein-Tyrosine Kinases genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-ret genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Cell Cycle Proteins genetics, ErbB Receptors genetics, Gene Fusion genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Microtubule-Associated Proteins genetics, Molecular Targeted Therapy, Precision Medicine trends, Receptor Protein-Tyrosine Kinases genetics, Serine Endopeptidases genetics
- Published
- 2014
21. [Picture in clinical hematology no. 70: ALK-positive-undifferentiated-large-cell intravascular lymphoma].
- Author
-
Shiroshita K, Kida J, Uemura M, Shintani T, Matsumoto K, Imataki O, Miyai Y, Haneba N, and Yamaoka M
- Subjects
- Aged, 80 and over, Anaplastic Lymphoma Kinase, Fatal Outcome, Humans, Immunohistochemistry, Lung Neoplasms pathology, Lymphoma, Large-Cell, Anaplastic enzymology, Male, Neoplasm Invasiveness, Splenic Neoplasms pathology, Vascular Neoplasms enzymology, Lymphoma, Large-Cell, Anaplastic pathology, Receptor Protein-Tyrosine Kinases analysis, Vascular Neoplasms pathology
- Published
- 2014
22. ALK inhibitor.
- Author
-
Sakamoto H
- Subjects
- Anaplastic Lymphoma Kinase, Clinical Trials as Topic, Crizotinib, Humans, Lung Neoplasms genetics, Receptor Protein-Tyrosine Kinases physiology, Small Cell Lung Carcinoma genetics, Drug Discovery, Molecular Targeted Therapy, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Pyrazoles pharmacology, Pyrazoles therapeutic use, Pyridines pharmacology, Pyridines therapeutic use, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Receptor Protein-Tyrosine Kinases genetics
- Published
- 2013
- Full Text
- View/download PDF
23. [Recent changes in the therapeutic strategy for NSCLC in association with new anti-cancer agents].
- Author
-
Yatabe Y
- Subjects
- Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents adverse effects, Carcinoma, Non-Small-Cell Lung genetics, Humans, Lung Neoplasms genetics, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, ErbB Receptors genetics, Lung Neoplasms drug therapy, Mutation genetics, Receptor Protein-Tyrosine Kinases genetics
- Abstract
Patients with SCLC (Small cell lung cancer) have been treated differently from those with NSCLC (New-small cell lung cancer) as a different disease. Recently, even patients with NSCLC are treated differently according to histological subtypes. This change is associated with the development of new drugs, particularly molecular-targeted drugs. Because Bevacizumab can cause serious adverse effects, patients with squamous cell carcinoma histology and a history of hemoptysis are contraindicated for this drug. Pemetrexed has been approved with an anti-mesothelioma drug and was confirmed to be effective for NSCLC. However, its efficacy was not equally proved among the histological subtypes; only adenocarcinoma patients showed shorter progression-free and prolonged survival periods. Regarding tyrosine kinase inhibitors, the targeted gene alterations occur specifically in adenocarcinoma. Based on these findings, the current therapeutic strategy for NSCLC is based on the histological subtype and mutational status of EGFR and ALK. In this article, transition of the therapeutic strategy for NSCLC, characteristics of targeted gene alterations and efficacies of the targeted therapy are reviewed.
- Published
- 2013
24. [Other intracellular tyrosine kinases (including ALK)].
- Author
-
Mano H
- Subjects
- Anaplastic Lymphoma Kinase, Drug Resistance, Neoplasm, Humans, Neoplasms drug therapy, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Receptor Protein-Tyrosine Kinases physiology, Protein-Tyrosine Kinases physiology
- Published
- 2012
25. [Molecular diagnosis of lung cancer in association with treatment of choice].
- Author
-
Yatabe Y and Shibata N
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma drug therapy, Adenocarcinoma of Lung, Anaplastic Lymphoma Kinase, ErbB Receptors genetics, Humans, Lung Neoplasms diagnosis, Lung Neoplasms genetics, Pathology, Molecular methods, Receptor Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases metabolism, Lung Neoplasms drug therapy
- Abstract
Recent advances in lung cancer research have enabled significant progress in our understanding of the molecular pathogenesis and treatment for lung cancer. For example, EGFR tyrosine kinase inhibitors have been developed, and a subset of patients show marked therapeutic responses to this treatment. Subsequently, this super-response was revealed to be associated with an EGFR mutation that was identified in 2005. Currently, EGFR tyrosine kinase inhibitors are available for first-line treatments of patients with advanced non-small-cell lung cancer when the tumor is positive for an EGFR mutation. More recently, similar marked responses to an ALK inhibitor in patients with ALK fusion lung cancers were demonstrated. In this article, we review such recent advances in lung cancer, focusing on EGFR mutation and ALK fusion..
- Published
- 2012
26. [ALK inhibitor].
- Author
-
Mano H
- Subjects
- Anaplastic Lymphoma Kinase, Animals, Humans, Lung Neoplasms enzymology, Lung Neoplasms genetics, Molecular Targeted Therapy, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Protein-Tyrosine Kinases genetics, Protein-Tyrosine Kinases metabolism, Receptor Protein-Tyrosine Kinases, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors
- Abstract
While lung cancer is the leading cause of cancer deaths worldwide, the molecular mechanism underlying its carcinogenesis is mainly unknown. We have discovered a small, fusion-type tyrosine kinase EML4-ALK that is generated through a tiny inversion within the short arm of human chromosome 2. Transgenic mice expressing EML4-ALK in lung developed hundreds of lung cancer nodules soon after birth, but such nodules were readily eradicated upon treatment with an ALK inhibitor. Clinical trials for EML4-ALK-positive lung cancer with an ALK inhibitor is ongoing, with its interim results being highly promising.
- Published
- 2011
27. [Cytoplasmic kinase inhibitors].
- Author
-
Mano H
- Subjects
- Anaplastic Lymphoma Kinase, Benzamides, Humans, Imatinib Mesylate, Janus Kinase 2 antagonists & inhibitors, Piperazines therapeutic use, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Pyrimidines therapeutic use, Receptor Protein-Tyrosine Kinases, Protein-Tyrosine Kinases antagonists & inhibitors
- Abstract
Protein kinases play essential roles in the regulation of cell proliferation. Point mutations or/and fusions of protein kinases are frequently identified in human cancers, and targeting such activated kinases provides us with a chance to eradicate tumor cells. This was first proved by imatinib mesylate that inhibits ABL tyrosine kinase and, thereby, efficiently kills malignant cells in chronic myeloid leukemia. In addition, other clinical trials are ongoing for kinase inhibitors against EML4--ALK in lung cancer, JAK2 in myeloproliferative disorders and BRAF in malignant melanoma. Early reports indeed reveal that such targeting compounds are promising drugs for human cancers with activated kinases.
- Published
- 2010
28. [New molecular targeted EML4-ALK for lung cancer].
- Author
-
Mano H
- Subjects
- Anaplastic Lymphoma Kinase, Animals, Drug Delivery Systems, Humans, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Receptor Protein-Tyrosine Kinases, Lung Neoplasms diagnosis, Oncogene Proteins, Fusion analysis, Protein-Tyrosine Kinases antagonists & inhibitors
- Published
- 2009
29. [Oncogenic mutations of ALK are associated with tumorigenesis of neuroblastoma].
- Author
-
Takita J and Ogawa S
- Subjects
- Anaplastic Lymphoma Kinase, Animals, Cell Division genetics, Genomics, Humans, Neuroblastoma pathology, Phosphorylation, Polymorphism, Single Nucleotide genetics, Receptor Protein-Tyrosine Kinases, Mutation, Missense, Neuroblastoma genetics, Protein-Tyrosine Kinases genetics
- Published
- 2009
30. [ALK-negative primary gastric anaplastic large cell lymphoma].
- Author
-
Koizumi K, Minauchi K, Odani T, Kondo M, Takada A, and Mukai M
- Subjects
- Anaplastic Lymphoma Kinase, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cisplatin administration & dosage, Combined Modality Therapy, Epirubicin administration & dosage, Etoposide administration & dosage, Female, Humans, Ifosfamide administration & dosage, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse pathology, Middle Aged, Peripheral Blood Stem Cell Transplantation, Receptor Protein-Tyrosine Kinases, Remission Induction, Salvage Therapy, Stomach Neoplasms diagnosis, Stomach Neoplasms pathology, Transplantation, Autologous, Biomarkers, Tumor analysis, Lymphoma, Large B-Cell, Diffuse therapy, Protein-Tyrosine Kinases analysis, Stomach Neoplasms therapy
- Abstract
A 56-year-old Japanese woman was admitted to our hospital with upper abdominal pain. Gastroendoscopy revealed a Borrmann III type tumor which was diagnosed from the biopsied specimen as an anaplastic large cell lymphoma (ALCL). CT scan revealed para-aortic and left-supra clavicular lymph node swelling, so her clinical stage was defined as IIIE according to the Ann Arbor classification. The patient first of all received CHOP therapy, however her lymphoma lesions increased in size. Therefore she underwent salvage chemotherapy regimens and autologous peripheral blood stem cell transplantation (APBSCT). She has remained in complete clinical remission (CCR) for eleven months after the APBSCT.
- Published
- 2007
31. [A case of inflammatory myofibroblastic tumor of the urinary bladder finally diagnosed by anaplastic lymphoma kinase (ALK) immunostaining].
- Author
-
Takeshita H, Kawakami S, Okubo Y, Yamamoto S, Yonese J, Fukui I, Kono A, Kurata M, Inoshita N, and Ishikawa Y
- Subjects
- Anaplastic Lymphoma Kinase, Cystoscopy, Diagnosis, Differential, Female, Granuloma, Plasma Cell surgery, Humans, Magnetic Resonance Imaging, Middle Aged, Pelvic Exenteration, Receptor Protein-Tyrosine Kinases, Urinary Bladder Neoplasms surgery, Granuloma, Plasma Cell pathology, Protein-Tyrosine Kinases analysis, Urinary Bladder Neoplasms pathology
- Abstract
A 52-year-old house wife presented with pain on urination. Cystoscopy and magnetic resonance imaging revealed solid and sessile tumor of 3 cm in diameter invading the bladder wall. Pathological examination of the transurethral resection specimen showed proliferation of spindle cells and epithelial cells. Since both types of cells were positive for cytokeratin immunostaining, sarcomatoid carcinoma was highly suspected. She underwent anterior pelvic exenteration and construction of continent reservoir (Penn Pouch). Since the tumor cells showed spindle cell proliferation alone without epithelial growth and positive staining for anaplastic lymphoma kinase, we corrected the final diagnosis as an inflammatory myofibroblastic tumor of the urinary bladder. She has been doing well without recurrence for 1 year.
- Published
- 2006
32. [CD30-negative diffuse large B-cell lymphoma expressing ALK].
- Author
-
Ishii K, Yamamoto Y, and Nomura S
- Subjects
- Adult, Anaplastic Lymphoma Kinase, Combined Modality Therapy, Fatal Outcome, Humans, Ki-1 Antigen, Male, Peripheral Blood Stem Cell Transplantation, Peripheral Vascular Diseases etiology, Receptor Protein-Tyrosine Kinases, Transplantation, Homologous, Lymphoma, B-Cell classification, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell genetics, Lymphoma, B-Cell therapy, Lymphoma, Large B-Cell, Diffuse classification, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse therapy, Protein-Tyrosine Kinases
- Abstract
A 33-years-old man was diagnosed as having undifferentiated carcinoma presenting with right neck lymphadenopathy in December 2000. He obtained complete remission (CR) following chemotherapy, radiation and lymphadenectomy on the right neck. He had multiple para-aorta lymphadenopathy and splenomegaly in December 2001. An open-abdominal lymph node biopsy was performed from which a diagnosis of anaplastic large cell lymphoma was made. CR was achieved with biweekly CHOP, however, the patient suffered from a relapse twice. He underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from his HLA-matched sister while in non-CR in November 2002. Engraftment was achieved on day 14, and at the same time, complete chimerism was confirmed. Acute grade III graft-versus-host disease (GVHD) developed and was controlled with cyclosporine A and prednisolone. Extensive chronic GVHD was subsequently observed and required systemic immunosuppression. His condition returned to CR after the PBSCT and he sustained complete chimerism. He suddenly died of fulminant thrombotic microangiopathy seven months after the PBSCT. The tumor cells were ALK-positive, CD30-negative and JH rearrangement was detected, and were therefore classified as diffuse large B-cell lymphoma with expression of ALK according to the WHO classification, though they differed from this subtype in some points. Although this case was refractory for chemotherapy with a complex karyotype, the graft-versus-lymphoma effect might have contributed to the sustained CR following the PBSCT.
- Published
- 2005
33. [Anaplastic large cell lymphoma].
- Author
-
Suzukawa K, Kojima H, and Nagasawa T
- Subjects
- Anaplastic Lymphoma Kinase, Animals, Chromosomes, Human, Pair 2, Chromosomes, Human, Pair 5, Humans, Nuclear Proteins genetics, Nucleophosmin, Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases, Lymphoma, Large-Cell, Anaplastic classification, Lymphoma, Large-Cell, Anaplastic genetics
- Published
- 1998
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.